PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.99%
Revenue growth at 50-75% of MRVL's 11.56%. Martin Whitman would worry about competitiveness or product relevance.
10.72%
Gross profit growth at 50-75% of MRVL's 14.43%. Martin Whitman would question if cost structure or brand is lagging.
8.22%
EBIT growth below 50% of MRVL's 127.66%. Michael Burry would suspect deeper competitive or cost structure issues.
8.22%
Operating income growth under 50% of MRVL's 127.66%. Michael Burry would be concerned about deeper cost or sales issues.
-28.46%
Negative net income growth while MRVL stands at 117.98%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-4.55%
Negative EPS growth while MRVL is at 119.69%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
No Data
No Data available this quarter, please select a different quarter.
-33.13%
Share reduction while MRVL is at 1.76%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-34.35%
Reduced diluted shares while MRVL is at 8.67%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
53.69%
Dividend growth of 53.69% while MRVL is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-63.17%
Negative OCF growth while MRVL is at 131.35%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-101.01%
Negative FCF growth while MRVL is at 189.96%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
0.94%
10Y revenue/share CAGR under 50% of MRVL's 117.37%. Michael Burry would suspect a lasting competitive disadvantage.
32.83%
5Y revenue/share CAGR under 50% of MRVL's 117.37%. Michael Burry would suspect a significant competitive gap or product weakness.
18.57%
3Y revenue/share CAGR under 50% of MRVL's 117.37%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-19.88%
Negative 10Y OCF/share CAGR while MRVL stands at 334.23%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
67.07%
Below 50% of MRVL's 334.23%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
237.16%
3Y OCF/share CAGR at 50-75% of MRVL's 334.23%. Martin Whitman would suspect weaker recent execution or product competitiveness.
130.60%
Positive 10Y CAGR while MRVL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
32.77%
Positive 5Y CAGR while MRVL is negative. John Neff might view this as a strong mid-term relative advantage.
62.90%
Positive short-term CAGR while MRVL is negative. John Neff would see a clear advantage in near-term profit trajectory.
309.80%
Below 50% of MRVL's 5425.82%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
66.92%
Below 50% of MRVL's 5425.82%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-5.11%
Negative 3Y equity/share growth while MRVL is at 5425.82%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
83.26%
Dividend/share CAGR of 83.26% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
3.43%
Dividend/share CAGR of 3.43% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
2.09%
3Y dividend/share CAGR of 2.09% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
15.64%
AR growth well above MRVL's 4.52%. Michael Burry fears inflated revenue or higher default risk in the near future.
16.67%
Inventory growth well above MRVL's 17.78%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.77%
Similar asset growth to MRVL's 1.63%. Walter Schloss finds parallel expansions or investment rates.
52.33%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
-0.36%
We’re deleveraging while MRVL stands at 26.44%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
10.27%
R&D growth drastically higher vs. MRVL's 9.23%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
14.94%
SG&A growth well above MRVL's 16.00%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.